Desmond Tutu Health Foundation Celebrates Landmark Achievement in HIV Prevention with Gilead’s Lenacapavir Study
Cape Town, South Africa – June 21, 2024 – Gilead Sciences announced the groundbreaking results of the Phase 3 PURPOSE 1 study yesterday, which demonstrated that twice-yearly injections of Lenacapavir achieved 100% efficacy and superiority to daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for HIV prevention in cisgender women. The Desmond Tutu Health Foundation (DTHF) contributed to…
Details